Hemoglobin Based Oxygen Therapeutics in Elective Percutaneous Coronary Revascularization

Summary

The test compound and subject of this clinical trial is the haemoglobin-based oxygen carrier, HBOC-201 (Hemopure). HBOC-201, initially developed as an alternative to red blood cells for surgical patients, has the ability to restore tissue oxygenation in persistently ischemic tissue. The development of this new class of compounds, referred to as oxygen therapeutics, provides an opportunity to test the safety and efficacy of a new approach to management of myocardial ischemia.

Timeline

Start

2007-04

Primary completion

2008-03

Completion

2008-04

Drugs

Indications